Trial data comparison: difference between revisions
Diff·revision 31 → 32·01:09, 22 May 2025
Difference between revision 31 and revision 32 of Trial data comparison. 1 line changed; the page grew by 82 bytes.
| Revision 31 — 21:07, 12 May 2025 StabilityStig (talk) ce 4,355 bytes ±0 | Revision 32 — 01:09, 22 May 2025 CPeptidePaddy (talk) rv addition of price information per PP:VN 4,437 bytes +82 | ||
|---|---|---|---|
| 12 | }} | 12 | }} |
| 13 | {{hatnote|For the programmes themselves, see [[STEP trial programme]], [[SURMOUNT trial programme]], [[SURPASS trial programme]] and [[TRIUMPH trial programme]].}} | 13 | {{hatnote|For the programmes themselves, see [[STEP trial programme]], [[SURMOUNT trial programme]], [[SURPASS trial programme]] and [[TRIUMPH trial programme]].}} |
| + | 14 | {{refimprove|date=May 2026|talk=Cross-trial tabulation and the estimand problem}} | |
| 14 | 15 | ||
| 15 | The '''trial data comparison''' tabulates the principal published results of the major randomised trials of [[GLP-1 receptor agonist|GLP-1 receptor agonists]] and related compounds, so that a reader arriving at one figure can see the others alongside it. Each row is attributed to its trial, arm, duration and comparator. | 16 | The '''trial data comparison''' tabulates the principal published results of the major randomised trials of [[GLP-1 receptor agonist|GLP-1 receptor agonists]] and related compounds, so that a reader arriving at one figure can see the others alongside it. Each row is attributed to its trial, arm, duration and comparator. |